Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study

NCT04328961 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04328961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04328961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded, Randomized Study
Lead sponsor
University of Washington
Phase
Phase 2/3
Overall status
Completed
Start date
March 31, 2020
Completion date
October 8, 2020
Enrollment
943 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, covid-19, sars (severe acute respiratory syndrome), sars-cov-2